Table 2.
Results of meta-analysis analyzing the levels of inflammatory biomarkers in patients with COVID-19 treated with nitazoxanide compared to placebo
| Laboratory findings | SMD | 95% CI | I2 | p-value | Magnitude of effect |
|---|---|---|---|---|---|
| WBC | − 0.15 | − 0.29 to − 0.02 | 0% | 0.03 | Small |
| Neutrophils | − 0.07 | − 0.21 to 0.07 | 0% | 0.32 | No effect |
| Lymphocytes | − 0.07 | − 0.21 to 0.06 | 0% | 0.29 | No effect |
| LDH | − 0.32 | − 0.52 to -0.13 | NA | < 0.01 | Small to moderate |
| IL-6 | − 0.48 | − 1.51 to 0.55 | 89% | 0.36 | No effect |
| IL-8 | − 0.25 | − 0.92 to 0.42 | 77% | 0.47 | No effect |
| TNF-α | − 0.30 | − 0.91 to 0.31 | NA | 0.33 | No effect |
| CRP | − 0.36 | − 1.00 to 0.27 | 94% | 0.26 | No effect |
| D-dimer | − 0.49 | − 0.68 to − 0.31 | 0% | < 0.01 | Small to moderate |
WBC white blood cells, LDH lactate dehydrogenase, CRP C-reactive protein, SMD standardized mean difference, NA not applicable